AU2002346834A1 - Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain - Google Patents
Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic painInfo
- Publication number
- AU2002346834A1 AU2002346834A1 AU2002346834A AU2002346834A AU2002346834A1 AU 2002346834 A1 AU2002346834 A1 AU 2002346834A1 AU 2002346834 A AU2002346834 A AU 2002346834A AU 2002346834 A AU2002346834 A AU 2002346834A AU 2002346834 A1 AU2002346834 A1 AU 2002346834A1
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- affective
- compound
- formula
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Description
MONOHYDROXYCARBAMAKEPINE FOR USE IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DISORDER AND NEUROPATHIC PAIN
The present invention relates to new pharmaceutical uses of a carbamazepine derivative.
More particularly the present invention relates to new pharmaceutical uses for monohydroxycarbamazepine of formula I
Monohydroxycarbamazepine (10-hydroxy-10,11-dihydro-carbamazepine), the main metabolite of the antiepileptic oxcarbazepine (Trileptal ®) is well known from the literature [see for example Schuetz H. et al., Xenobiotica (GB), 16(8), 769-778 (1986)] and can be prepared synthetically starting from oxcarbazepine according to conventional methods. Monohydroxycarbamazepine has been first disclosed in GB 1310120. The compound is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
In accordance with the present invention, it has now surprisingly been found that the compound of formula I is useful in the treatment of affective and attention disorders including e.g. depression and bipolar mood disorders; as well as neuropathic pain and related disorders.
The activity of the compound of formula I in the treatment of affective and attention disorders and of neuropathic pain is evidenced, for example, by its ability to inhibit gamma- aminobutyric acid (GABA) turnover. This is due to feedback inhibition caused by the activating effect of these compounds on GABA transmission.
The role of GABA in bipolar and other mood disorders is unquestioned and topic of several reviews (e.g., Emrich et al. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr. 1980; 229:1-16; Petty. GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. 1995; 34:275-81). Drugs effective
in (bipolar) mood disorders and also in anxiety and depression, e.g. lithium, valproate and diazepam are known to inhibit the GABA turnover rate. This is due to feedback inhibition caused by the activating effect of these compounds on GABA transmission.
Also, the role of GABA in chronic pain is unquestioned and topic of several reviews (e.g., Stamford. Descending control of pain. Br. J. Anaesth. 1995; 75:217-21). Drugs effective in chronic pain such as valproate are known to inhibit the GABA turnover rate. This is due to feedback inhibition caused by the activating effect of these compounds on GABA transmission.
The activity of the compound of formula I on GABA turnover is evidenced in the following experiment:
The determination of GABA turnover is based on the linear increase in GABA level observed after the maximal inhibition of gamma- aminobutyric acid transaminase (GABA-T). The values obtained with this approach for the rate of GABA synthesis are independent of the inhibitors used and within the catalytic capacity of the enzymes involved in the GABA shunt.
Under these conditions, the compound of formula I dose-dependently inhibits the GABA turnover rate at doses of 30 to about 300 mg/kg p.o.
The activity of the compound of formula I in the treatment of affective and attention disorders treatment is also evidenced, for example, in tests suitable for detecting drugs having potential behavioural desinhibitory and/or sociotropic effects which are thought to be relevant for recovery from social withdrawal, a cardinal feature of depression and related psychiatric conditions. For instance, drug effects on social withdrawal of intruder mice can be evaluated by using the basic method as described in Triangle, 1982, 21:95-105 and J. Clin. Psychiatry, 1994, 55:9 (suppl. B) 4-7.
Within the dose range of 1 to about 100 mg/kg p.o., the compound of formula I increases social investigation in the treated mouse under such experimental conditions.
In view of its anxiolytic-/antidepressant- like stimulating effect on GABA transmission and sociotropic activity, the compound of formula I is useful in the treatment of affective disorders
including depression and bipolar disorders, e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired. In addition, the compound is indicated in ADHD (attention deficit hyperactivity disorders) and other attention disorders, e.g. autism, (and) in anxiety states, generalized anxiety and agoraphobia, as well as those behavioural states characterized by social withdrawal e.g. negative symptoms.
The direct activity of the compound of formula I in the treatment of neuropathic pain is evidenced, for example, in the following model of neuropathic pain in the guinea pig:
Dunkin Hartley guinea pigs are anaesthetised with enflurane (in N2O:O2 for guinea pigs) and the left sciatic nerve is exposed and partially ligated with thread. This procedure produces a mechanical hyperalgesia, which develops within 2-3 days and is maintained for at least 4 weeks. Paw withdrawal thresholds to a pressure stimulus are measured using an analgesymeter. Mechanical thresholds are taken on both the ipsilateral (ligated) and contralateral (unligated) paw prior to and then up to 6 hours following drug or vehicule administration. Reversal of hyperalgesia at each time point is calculated. Groups of 6 animals are used. Statistical analysis is carried out on withdrawal threshold readings using ANOVA followed by Tukey's HSD test.
In this model, the compound of formula I significantly and dose-dependently reverses neuropathic mechanical hyperalgesia at doses of 10 to about 100 mg/kg p.o. and 3 to about 100 mg/kg s.c.
The activity of the compound of formula I in the treatment of neuropathic pain and related disorders can be confirmed in clinical trials evaluating the efficacy of a compound in treating chronic pain in patients with diabetic neuropathy.
In such studies, the compound of formula I is found to decrease pain severity ratings relative to placebo during the Maintenance and Follow-up Periods, in a statistical significant way.
The compound of formula I is therefore useful in the treatment of neuropathic pain and associated hyperalgesia, including trigeminal and herpetic neuralgia, diabetic neuropathic
pain, migraine, causalgia and deafferentation syndromes such as brachial plexus avulsion, and in spasticity and related disorders.
For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.05 to about 150, preferably from about 0.1 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 0.5 to about 5000, preferably from about 1 to about 500mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form, for example once a day.
The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
The agents of the invention can be administered in vivo either alone or in combination with other pharmaceutical agents, e.g. agents effective in the treatment of diseases and conditions in which the human VR1 activation plays a role or is implicated including cyclooxygenase-2 (COX-2) inhibitors, such as specific COX-2 inhibitors (e.g. celecoxib, COX189, and rofecoxib) or in general nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. acetylsalicylic acid, propionic acid derivatives), tricyclic antidepressants (e.g. Anafranil®, Asendin®, Aventyl®, Elavil®, Endep®, Norfranil®, Norpramin®, Pamelor®, Sinequan®, Surmontil®, Tipramine®, Tofranil®, Vivactil®, Tofranil-PM®), anticonvulsants (e.g. gabapentin), GABAB agonists (e.g. L-baclofen), opioids, Vanniloid receptor antagonists and Cannabinoid (CB) receptor agonists, e.g. CBι receptor agonists.
The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e. a single galenical composition comprising at least two combination partners, according to the invention can be prepared in a manner known per se and are thus suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination
with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.
The invention further provides the use of the compound of formula I for the manufacture of a pharmaceutical composition for the treatment of affective and attention disorders, neuropathic pain and neurophatic pain related disorders.
The invention furthermore provides a method for the treatment of affective and attention disorders, neuropathic pain and neurophatic pain related disorders in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the compound of formula I.
Claims (4)
1. The use of monohydroxycarbamazepine of formula
for the treatment of affective and attention disorders, neuropathic pain and neurophatic pain related disorders.
2. A pharmaceutical composition comprising the compound of formula I according toclaim 1 , in association with at least one pharmaceutical carrier or diluent, for use in the treatment of affective and attention disorders, neurophatic pain and neurophatic pain related disorders.
3. The use of the compound of formula I according to claim 1 , for the manufacture of a pharmaceutical composition for the treatment of affective and attention disorders, neurophatic pain and neurophatic pain related disorders.
4. A method for the treatment of affective and attention disorders, neurophatic pain and neurophatic pain related disorders in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the compound of formula I according to claim 1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007201925A AU2007201925B2 (en) | 2001-11-12 | 2007-05-01 | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
AU2009201388A AU2009201388A1 (en) | 2001-11-12 | 2009-04-08 | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0127177.4 | 2001-11-12 | ||
GB0127176.6 | 2001-11-12 | ||
GB0127178.2 | 2001-11-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007201925A Division AU2007201925B2 (en) | 2001-11-12 | 2007-05-01 | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002346834A1 true AU2002346834A1 (en) | 2003-05-26 |
Family
ID=
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004226827B2 (en) * | 2003-04-02 | 2008-04-03 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004226827B2 (en) * | 2003-04-02 | 2008-04-03 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007201925B2 (en) | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain | |
Hirooka et al. | Pressor and sympathoexcitatory effects of nitric oxide in the rostral ventrolateral medulla | |
JP5627160B2 (en) | Indole-3-propionic acid for use as a medicament, and salts and esters thereof | |
Pertovaara et al. | Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective α2‐adrenoceptor antagonist | |
WO2007127010A2 (en) | Diarylthiohydantoin compounds | |
Gyermek | The pharmacology of imipramine and related antidepressants | |
US11013740B2 (en) | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy | |
US20100120746A1 (en) | Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain | |
Geppetti et al. | Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid | |
AU2002346834A1 (en) | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain | |
ZA200402946B (en) | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorders and neuropathic pain. | |
Åberg et al. | Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis | |
RU2353365C2 (en) | Monohydroxycarbamazepine for medical preparation for affective and attention disorders and neuropathic pain | |
Leach et al. | Deliberate overdose with the novel anticonvulsant tiagabine | |
AU684711B2 (en) | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema | |
US5866566A (en) | Derivatives of 10, 11-Dihydro-10-OXO-5H-Dibenz/B,F/Azepine-5-carboxamide | |
US20030134894A1 (en) | Methods of treating mental diseases, inflammation and pain | |
US6054471A (en) | Use of fluorinated triazoles in treating neuropathic pain | |
US20020115617A1 (en) | Methods for the prevention and / or the treatment of glutamate cytotoxicity | |
EP1156856B1 (en) | Use of fluorinated triazoles for the treatment of neuropathic pain | |
US20040176344A1 (en) | Method to treat patients with amyotrophic lateral sclerosis and the like | |
EP3797769A1 (en) | Composition for therapeutic use | |
WO2019046534A1 (en) | Deuterated indoloquinoline compounds | |
KR20010029658A (en) | Agent for enhancing cerebral acetylcholine release | |
Rahimi et al. | Comparison of Esmolol and Labetalol effects on hemodynamic changes in Electro Convulsive Therapy a randomized controlled trial |